Drug Discovery

Here’s how an mRNA-based approach can overcome the development challenges of designing protein therapeutics.

Researchers use AI to reprogram glioblastoma cancer cells

Research suggests diabetes patients using SGLT-2 and DPP-4 inhibitors have a decreased risk of developing dementia.

We interview Lars Erwig, Director of the Centre of Drug Development at Cancer Research UK, about his career.

A recent US-based study discovered a new compound that could enhance naloxone’s ability to fend off more potent opioids.

The search for an effective treatment for childhood brain cancers goes on, but a modified Herpes virus could represent a breakthrough.

If used correctly, AI and ML expand our knowledge of biology and vastly improve the speed of success in the clinic.

We speak with the Alzheimer’s Society in the UK about their work. Find out more with The Medicine Maker

NervGen President and CEO Mike Kelly discusses the potential of the company’s investigational drug NVG-291 for spinal cord injury.

Check out our video interview with Debra Weiss from the Bill & Melinda Gates Medical Research Institute.